1,989 material Form 8-K filings that 1,593 companies we cover made with the SEC in August 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Twist Bioscience disclosed that Anthropic, PBC published a blog post on August 18, 2026, saying it had received data from a protein design campaign against 15 targets using Claude Opus 4.8 and Mythos Preview. Anthropic said it chose Twist as one of its independent evaluators to rapidly produce these AI-designed proteins at scale and test them for binding. The filing gives no financial terms, revenue figures, or contract value, so its effect on shareholders is not quantified.
Anthropic published a blog post on August 18, 2026 describing a multi-arm protein design campaign against 15 targets.
The campaign used Claude Opus 4.8 and Mythos Preview.
Anthropic named Twist Bioscience as one of its independent evaluators to produce and test AI-designed proteins for binding.
The filing is furnished under Item 7.01 and gives no financial figures for the arrangement.
Wrap Technologies, Inc. closed a registered direct offering on August 18, 2026, selling 8,571,609 shares of common stock or pre-funded warrants in lieu of shares at $1.40 per share. Gross proceeds were approximately $12.0 million before placement agent fees and other offering expenses, and the company plans to use them for working capital and general corporate purposes. Shareholders should note that the sale adds new shares to the count, which can dilute existing holders.
Offering closed August 18, 2026; the purchase agreement was signed August 16, 2026.
Total of 8,571,609 shares: 5,771,519 common shares plus pre-funded warrants for up to 2,800,090 shares, priced at $1.40 per share ($1.3999 per pre-funded warrant).
Gross proceeds of approximately $12.0 million before offering expenses; Maxim Group LLC was the sole placement agent.
Securities were sold under a Form S-3 shelf registration declared effective December 18, 2025.
Baxter entered into Amendment No. 2 to its credit agreement on August 18, 2026, raising the maximum net leverage ratio for five fiscal quarters ending September 30, 2026 through September 30, 2027, and removing Baxter World Trade SRL as a borrower. The same day, the company raised the aggregate purchase price cap on its cash tender offers for certain senior notes from $500 million to $600 million and said it expects to accept $600 million of tendered notes for settlement on August 20, 2026.
Amendment No. 2, dated August 18, 2026, raises the maximum net leverage ratio covenant for the five fiscal quarters ending September 30, 2026 through September 30, 2027.
The tender offer purchase price cap rose from $500 million to $600 million, excluding accrued interest.
Holders who tendered by 5:00 p.m. New York City time on August 17, 2026 and were accepted receive an early tender premium of $30 per $1,000 principal amount, with early settlement on August 20, 2026.
Tenders for the 2.539% Senior Notes due 2032 totaled $756,712,000 of $1,550,000,000 outstanding, and the proration factor for that series is 31.37%.
ReposiTrak, Inc. entered into a three-year executive employment agreement with CFO and Principal Accounting Officer John R. Merrill, effective August 18, 2026. The agreement sets a $325,000 base salary and grants 75,000 restricted shares, which matters to shareholders as a compensation and retention arrangement for the finance chief.
Base salary of $325,000, retroactive to May 16, 2026; target bonus 60% of base salary
Grant of 75,000 shares of restricted common stock vesting in four equal annual installments
Severance on termination without Cause or resignation for Good Reason: nine months of base salary plus COBRA coverage support, with double-trigger protection after a Change in Control
Martin Marietta entered into a $1.5 billion five-year senior unsecured revolving credit facility with JPMorgan Chase Bank, N.A. as administrative agent, replacing its existing credit agreement dated December 21, 2021. The filing states that no borrowings were outstanding under the existing facility before the new agreement, and the new facility expires August 18, 2031. The filing also sets a leverage ratio covenant that steps up to 4.75 to 1.00 after the closing of the previously announced Lhoist North America acquisition, which gives the company more room under the covenant during that period.
$1.5 billion senior unsecured revolving facility, dated August 18, 2026, with JPMorgan Chase Bank, N.A. as administrative agent
Replaces the Existing Credit Agreement dated December 21, 2021; no borrowings were outstanding under it before the new facility
Facility expires August 18, 2031; interest is based on Term SOFR or a base rate plus a ratings-based margin
Maximum leverage ratio of 3.75 to 1.00, rising to 4.75 to 1.00 for the first three fiscal quarters after the Lhoist North America acquisition closes
Centrus Energy's Compensation, Nominating & Governance Committee approved a one-time grant of performance-based restricted stock units to executive officers and certain senior leaders on August 15, 2026, under a new 2026 Supplemental Executive Incentive Plan. The awards vest only if the company meets specified milestones, including completing a first cascade at its Piketon, Ohio facility and achieving enrichment from a first cascade, and are forfeited if employment ends before vesting.
Grant approved August 15, 2026 under the 2026 Plan, which sits under the 2014 Equity Incentive Plan
CEO Amir V. Vexler's awards, valued at $5,000,000 at full achievement, vest 100% on the Final Milestone
Other named executive officers' awards vest 30% on the first cascade at Piketon, Ohio and 70% on the Final Milestone; named officers' values range from $1,300,000 to $2,000,000 at full achievement
Award agreements will be filed as exhibits to the Form 10-Q for the quarter ending September 30, 2026
Sezzle and WebBank entered into amended bank program agreements on August 12, 2026, adding two products, SezzleCash and Sezzle Send, to the existing loan program. For those two products WebBank will keep loans on its balance sheet up to an initial $30.0 million threshold, which it may raise to $150.0 million, and Sezzle's minimum tangible net worth requirement rises from $12.0 million to $100.0 million.
Agreements dated August 12, 2026 amend and restate the September 26, 2024 bank program agreements with WebBank.
WebBank will retain SezzleCash and Sezzle Send loans to maturity, with an initial retention threshold of $30.0 million, which WebBank may raise up to $150.0 million.
Minimum tangible net worth covenant increases from $12.0 million to $100.0 million; new termination events added for judgments, fines or penalties and financial covenant breaches.
Program term is unchanged and runs through September 27, 2029; full agreements to be filed with the Form 10-Q for the quarter ending September 30, 2026.
On August 18, 2026, EXL entered a $1 billion senior secured credit facility with PNC Bank as administrative agent, consisting of a $600 million revolver and a $400 million term loan that mature August 18, 2031. The company used the proceeds to repay about $532,678,050 under its Citibank credit agreement, which it terminated with no early termination penalties. The larger facility increases borrowing capacity and covenant flexibility, with proceeds available for working capital, acquisitions and share buybacks.
Facilities total $1 billion: a $600 million revolving credit facility and a $400 million term loan, both maturing August 18, 2031
Repaid about $532,678,050 under the Citibank credit agreement, terminated with no early termination penalties
Borrowings bear interest at Term SOFR or Daily Simple SOFR plus a 1.00% to 1.75% margin, set by total net leverage
Covenants require interest coverage of at least 3.00 to 1.00 and total net leverage of no more than 3.50 to 1.00; obligations are secured by substantially all company assets
IDT Telecom, a subsidiary of IDT Corporation, signed an amendment dated August 11, 2026 to its revolving credit agreement with TD Bank, N.A. The amendment extends the facility, which was due to mature on August 16, 2026, to July 15, 2029, and raises the bank's lending limit in May and December, which could affect how much credit is available to the subsidiary during those months.
Maturity of the revolving credit facility extended from August 16, 2026 to July 15, 2029.
Revolving credit limit increased to $50.0 million in May and December of each calendar year, from $25.0 million in all other months.
National Retail Solutions, Inc., IDT Payment Services, Inc. and IDT Payment Services of New York, LLC added as corporate guarantors.
Credit facility remains secured by assets of IDT Telecom and several affiliates; other material terms are unchanged.
AbbVie completed an underwritten offering of nine series of senior notes on August 18, 2026, totaling $10.0 billion in principal across floating rate notes maturing 2028 and fixed rate notes maturing 2028 through 2066. AbbVie expects to use the net proceeds to fund part of the cash consideration for its acquisition of Apogee Therapeutics and related fees, with any remainder for general corporate purposes.
Nine series of notes totaling $10.0 billion in aggregate principal, registered under AbbVie's Form S-3ASR dated February 14, 2025
Net proceeds to fund a portion of the cash consideration due to Apogee shareholders and related fees and expenses
If the Apogee acquisition is terminated or abandoned, AbbVie must redeem most series (not the 2056 or 2066 Notes) at 101% of principal plus accrued interest
Notes are unsecured and rank equally with AbbVie's existing and future unsecured, unsubordinated debt
Charter's subsidiaries Charter Communications Operating, LLC and Charter Communications Operating Capital Corp. closed a $4.75 billion offering of four series of senior secured notes on August 18, 2026. The filing says the notes are senior secured obligations guaranteed by the parent and subsidiary guarantors, and that the offering was made under an automatic shelf registration.
Four series issued: $1.75 billion 6.050% notes due 2032, $1.0 billion 6.600% notes due 2034, $1.0 billion 6.950% notes due 2036 and $1.0 billion 7.850% notes due 2056
Issue prices ranged from 99.839% to 99.937% of principal amount
Interest is payable each February 15 and August 15, starting February 15, 2027
Citigroup Global Markets Inc., Morgan Stanley & Co. LLC and Wells Fargo Securities, LLC were joint book-running managers
Brighthouse Financial appointed Deputy Chief Accounting Officer Richard A. Cook as Chief Accounting Officer, succeeding Melissa B. Pavlovich, who is leaving the company for a new opportunity. The filing says her departure is not related to financial statements, disclosures, or accounting principles and practices.
Richard A. Cook becomes Chief Accounting Officer effective September 3, 2026, succeeding Melissa B. Pavlovich.
Pavlovich informed the company on August 12, 2026 of her resignation; her last day is September 2, 2026.
Cook's offer letter sets an annual base salary of $425,000, a target short-term incentive of 60% of base salary, and an LTI target valued at $219,500.
Kennametal appointed Dawne Hickton and Richard Harshman as directors, effective September 1, 2026, with election proposed at the October 2026 annual shareholder meeting. The filing describes board additions rather than financial results, operations or a change in management.
Richard J. Harshman, 70, is the retired Executive Chairman and former CEO of ATI Inc.
Dawne Hickton, 68, is Chair and CEO of Cumberland Additive, Inc. and formerly led Jacobs' Critical Mission Solutions business.
Neither director will immediately serve on a Board committee; both are expected to join committees in the coming months.
Both will sign indemnification agreements with the company, and the filing reports no related-party transactions.
Robert Eckert, a Class III director who had served on Levi Strauss & Co.'s board since 2010, retired on August 14, 2026, after reaching the company's mandatory retirement age of 72. The board reduced its size to ten directors, and Joshua Prime was named chair of the Nominating, Governance and Corporate Citizenship Committee.
Robert Eckert retired from the board on August 14, 2026, having reached the mandatory retirement age; he had served since 2010.
Eckert had most recently been board chair until April 2026, and chair of the NGCC Committee.
Joshua Prime was appointed to the NGCC Committee and named its chair, effective upon Eckert's retirement.
The company said the retirement is not the result of any disagreement with the company on operations, policies or practices.
nVent Electric said Randolph A. Wacker, who had announced plans to retire effective September 1, 2026, will instead stay on as Senior Vice President and Chief Accounting Officer. The Board appointed him to that role on August 14, effective September 1, 2026. For shareholders, this keeps the company's principal accounting officer in place and removes a planned leadership transition from the picture.
Randolph A. Wacker had previously announced plans to retire effective September 1, 2026, disclosed in a June 17, 2026 Form 8-K.
The Board appointed Wacker as Senior Vice President and Chief Accounting Officer on August 14, effective September 1, 2026.
Tyler Krutzig will continue as Assistant Corporate Controller.
The filing was signed by CFO Gary L. Corona on August 18, 2026.
Diodes completed a private offering of $375 million of 0.00% convertible senior notes due August 15, 2031, including the full exercise of a $50.0 million option, and amended its senior credit agreement to extend the revolver maturity to August 12, 2031 and permit the new debt. The notes carry a conversion price of about $145.79 per share, a 50.0% premium to the $97.19 closing price on August 13, 2026, so the offering adds debt that may dilute shareholders if the stock rises above that level.
Offering of $375 million principal closed August 18, 2026, including $50.0 million from the full exercise of the initial purchasers' option
Notes mature August 15, 2031; no regular interest; conversion price about $145.79 per share
Net proceeds estimated at $364.6 million with the option exercised, after costs; $35.0 million used to repurchase about 0.36 million shares at $97.19
Credit agreement amendment, effective August 12, 2026, extends revolver maturity to August 12, 2031 and changes pricing and covenants
Halozyme Therapeutics elected Dannielle Appelhans to its Board of Directors on August 14, 2026, in the class with terms ending at the 2028 annual meeting. She was not initially assigned to any Board committee, and the filing says she will receive compensation under the standard non-employee director program.
Board election effective August 14, 2026; term ends at the 2028 annual meeting of stockholders
Not initially assigned to any Board committee
Compensation follows the non-employee director program (cash retainers, restricted stock and stock options)
Filing states no arrangements or related person transactions with the company
York Water's Board appointed David M. Velazquez, former President and CEO of PECO Energy, as a new independent director, effective September 1, 2026. The filing says he has more than 40 years of energy and utility industry experience and will sit on the Board's Executive Committee.
Appointed at the Board's August 17, 2026 regularly scheduled meeting, effective September 1, 2026
Term expires at the 2027 Annual Meeting of Shareholders
Will be assigned to the Board's Executive Committee
Filing states no related-party transaction requiring disclosure under Item 404(a) of Regulation S-K
Rexford Industrial Realty agreed on August 13, 2026 to sell a portfolio of 22 industrial properties to an affiliate of EQT Real Estate for about $1.2 billion in cash, subject to customary closing adjustments. The sale is part of a previously announced $2.0 billion disposition program of non-core assets, and the company reaffirmed its 2026 guidance. Shareholders will watch whether the closing occurs by the expected September 30, 2026 date and how the net proceeds are used.
22 industrial properties, aggregate purchase price of about $1.2 billion payable in cash at closing
Closing expected by September 30, 2026; not subject to a due diligence condition
Company says the deal brings 2026 dispositions closed or under contract to about $1.5 billion, within its $1.5 to $2.0 billion full-year guidance range
Net proceeds may fund repayment of debt maturing in 2027 and repurchases under the $1.0 billion share repurchase program
On August 12, 2026, Universal Technical Institute entered a five-year senior secured revolving credit agreement with Fifth Third Bank and four other lenders, replacing its existing credit agreement in full. The new facility is larger than the prior $125 million facility and matures in August 2031, and the company's subsidiaries guarantee the debt and secure it with their assets, subject to certain exceptions.
Facility of up to $200 million, up from $125 million in the existing facility, with a $15 million swingline sublimit and a $75 million letter of credit sublimit
Uncommitted incremental capacity of up to $75 million in aggregate; facility matures in August 2031
The U.S. District Court for the Eastern District of New York granted final approval on August 14, 2026, to settle two shareholder derivative lawsuits against Virgin Galactic. The company said the settlement resolves all pending claims, with no finding of wrongdoing by the company or its directors or officers, which removes the litigation as an open matter for shareholders.
Court order dated August 14, 2026 grants final approval of the settlement of the In re Virgin Galactic Holdings, Inc. Derivative Litigation and St. Jean v. Branson derivative actions
Company's insurers will pay $2.75 million; Virgin Galactic will keep half, and the remaining half goes to plaintiffs' counsel for attorneys' fees and costs
All related claims are fully released, and the settlement involves no finding of wrongdoing by the company or any of its directors or officers
Inspired Entertainment said its General Counsel and EVP Simona Camilleri will step down effective September 7, 2026, and that Carys Damon, the current Company Secretary, will take on the General Counsel role on that date while keeping her Company Secretary title. The change is an executive handover, with no financial results or guidance included in the filing, so its impact on shareholders appears limited.
Simona Camilleri's role as EVP and General Counsel ends effective September 7, 2026; she remains on garden leave until December 31, 2026
Carys Damon, Company Secretary since July 2024 and a Company employee since 2012, becomes EVP and General Counsel effective September 7, 2026
Ms. Damon will be responsible for the Company's legal and compliance functions
Xylem said CFO William Grogan will resign effective August 31, 2026 to pursue another opportunity, and Andrea van der Berg, currently SVP Finance for the Water Infrastructure segment, will become CFO on September 1, 2026. Xylem also reaffirmed its third-quarter and full-year 2026 guidance issued July 28, 2026, which matters to shareholders because it signals no change to the outlook alongside the finance leadership change.
Grogan remains employed through September 13, 2026 to support the transition.
Van der Berg's annual base salary is $675,000, with an AIP target of 80% of base salary.
Van der Berg receives a one-time 2026 LTIP award with a grant date value of $787,500, and a new LTIP target award of $1,750,000.
Xylem reaffirmed its third-quarter and full-year 2026 guidance issued July 28, 2026.
Privia Health Group's board elected Opella Ernest, M.D., a former HCSC executive, as a Class III director effective September 1, 2026, and named her to the Compliance Committee. The change adds a director to the board and carries a $200,000 grant-date value equity award, but the filing does not describe any financial results or operational impact.
Dr. Ernest was elected by the board on August 12, 2026, effective September 1, 2026.
She was appointed to the Compliance Committee effective September 1, 2026.
Non-employee director pay includes an annual cash retainer and restricted stock units with a $200,000 grant-date fair market value.
Dr. Ernest is currently President, HCSC Markets at Health Care Service Corporation, a role held since 2023.
GE HealthCare appointed William K. Grogan, currently executive vice president and CFO of Xylem Inc., as Chief Financial Officer effective September 14, 2026, succeeding interim CFO George Newcomb, who will remain Controller and Chief Accounting Officer. The filing sets out his pay package, including a $900,000 base salary, a 100% target bonus, and sign-on awards to offset compensation forfeited at Xylem, which matters to shareholders as it defines the company's new top finance executive and its compensation commitments.
Grogan, age 48, has been Xylem's EVP and CFO since October 2023 and was IDEX Corporation's CFO from January 2017 to September 2023.
Offer letter: $900,000 base salary, target annual bonus of 100% of salary, and a 2026 annual LTI award with a $3,300,000 target grant date value.
Sign-on payments include $550,000 in cash and a $4,000,000 RSU award, with cash repayment required if he resigns within two years.
Newcomb ceases as interim CFO on September 14, 2026, and continues as Controller and Chief Accounting Officer.
BioMarin agreed on August 17, 2026 to acquire Alesta Therapeutics, a Dutch clinical-stage biotech, for a $275 million upfront cash payment plus up to $215 million in future payments tied to development milestones. Alesta will first spin out its non-ALE1 assets, and BioMarin expects to fund the deal with cash on hand and to update its full-year 2026 guidance after closing; the company says the deal is expected to be modestly dilutive to 2026 results excluding the upfront payment.
Upfront cash payment of $275 million, subject to a customary post-closing price adjustment, plus up to $215 million in milestone-based payments
Lead asset ALE1 is an oral small molecule in a Phase 1/2a trial for hypophosphatasia, a rare genetic bone disease
Closing expected in the third quarter of 2026, subject to closing conditions; BioMarin plans to fund the deal with cash on hand
Filing states the deal is expected to be modestly dilutive to 2026 results, excluding the upfront consideration
Entera Bio appointed Dr. Riccardo Paolo Camisasca as Chief Medical Officer effective August 18, 2026. The company said the hire comes ahead of the planned Phase 3 initiation of its EB613 oral osteoporosis candidate, which it describes as its most advanced product candidate.
Dr. Riccardo Paolo Camisasca appointed Chief Medical Officer, effective immediately on August 18, 2026
Dr. Camisasca has more than 30 years of experience, most recently as Global Head of Research & Development at Sumitomo Pharma Switzerland
Company plans to initiate a Phase 3 program for EB613, its oral PTH(1-34) tablet candidate for osteoporosis
Nano Dimension appointed Nadav Kidron as an independent director on August 16, 2026, effective immediately, with seats on the Audit and Compensation Committees. In a separate Regulation FD disclosure, the company said the 30-day exclusivity period under a non-binding term sheet with Infinite Epigenetics expired on July 15, 2026, and no definitive agreement has been reached.
Nadav Kidron appointed to the Board as a Class II director effective August 16, 2026, serving until the 2026 annual meeting
Kidron to serve on the Audit Committee and Compensation Committee; Board determined he is independent under Nasdaq rules
Exclusivity under the non-binding term sheet with Infinite Epigenetics, Inc. expired July 15, 2026
As of the filing date, the parties have not agreed on terms of a definitive agreement
Epsilon Energy filed an August 2026 corporate presentation as Exhibit 99.1 to a Form 8-K, furnished under Regulation FD. The deck outlines a plan for more than 20% annual production growth over 2026 to 2028 while keeping leverage below 1.5X, and it sets Q3 and full-year 2026 production and capital ranges.
Full-year 2026 total production guidance of 13,740 to 14,280 MMcfe, with capital spending of $42.0 million to $47.0 million.
Q3 2026 total production guidance of 3,270 to 3,510 MMcfe, with capital spending of $24.0 million to $28.5 million.
Net debt to LTM EBITDA leverage was 0.9X as of June 30, 2026, per the presentation.
Development inventory of 216 net locations in total, with 115 net priority locations, according to the presentation.
Copart appointed David J. Berger as a director effective August 13, 2026, with a term running to its 2026 annual meeting. Berger is a senior partner at Wilson Sonsini Goodrich & Rosati, which the company uses as outside corporate counsel, and the company expects to use that firm for routine legal work going forward, with fees it considers not material.
Berger joined the board effective August 13, 2026; his initial term expires at the 2026 annual meeting of stockholders
Berger is a senior partner at Wilson Sonsini, Copart's outside corporate counsel, and the company expects routine engagements with the firm; fees for fiscal 2027 are expected to be not material
Company says no related party transactions requiring disclosure under Item 404(a) for fiscal year ended July 31, 2026
Announced in a press release dated August 17, 2026; Berger will join the outside director compensation program and has signed the standard indemnification agreement
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.